HOME
SEARCH
RSS FEED
SUBSCRIBE
Search Results - Therapeutics
23
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Enhancing Methotrexate Efficacy for Ectopic Pregnancy Treatment
Methotrexate (MTX) loaded polymersomes are used to preferentially deliver MTX to sites of ectopic pregnancy Background Ectopic pregnancy, abnormal pregnancy implantation at sites other than in the uterine cavity, leads to internal bleeding if not identified and treated in a timely manner, and is a major cause of maternal morbidity and mortality....
Published: 9/5/2024
|
Inventor(s):
Olena Taratula
,
Oleh Taratula
,
Maureen Baldwin
,
Leslie Myatt
,
Babak Mamnoon
Keywords(s):
Category(s):
Therapeutics
Biosynthetic Gene Cluster for the Peptide Antibiotic Enduracidin
Background The emerging and persistent threat of multidrug-resistant bacterial infections has resulted in enormous healthcare costs and poses major challenges to public health. To address the need for new antibiotics capable of combating the gowning problem of resistance, Oregon State University researchers cloned and patented the biosynthetic gene...
Published: 9/12/2024
|
Inventor(s):
T. Zabriskie
,
Xihou 希厚 Yin 银
Keywords(s):
Biomedical
,
Biotechnology
,
Medical Science & Technologies
,
pharmaceuticals
Category(s):
Therapeutics
mRNA Therapeutic Against the SARS-CoV-2 Spike Protein
Background Vaccines have shown great efficacy against SARS-CoV-2, the pathogen of COVID-19; however, methods of treatment are required for patients suffering from COVID‑19. More than 15 million cases with over 600,000 deaths have resulted from the ongoing coronavirus disease 2019 (COVID-19). SARS-CoV-2, the pathogen of COVID-19, is a β-coronavirus...
Published: 8/4/2022
|
Inventor(s):
Gaurav Sahay
,
Anindit Mukherjee
,
Jeonghwan Kim
Keywords(s):
antiviral
,
Drug
,
Drug Delivery
,
mRNA
,
mRNA carrier
,
mRNA delivery
Category(s):
Therapeutics
Treatment for Metabolic Syndrome and Obesity Related Diseases
Background Abdominal obesity is the most commonly observed component of metabolic syndrome and a major risk factor for type II diabetes and cardiovascular disease. In addition to obesity, an individual’s risk of cardiovascular disease and type II diabetes is strongly correlated to a series of risk factors, collectively referred to as metabolic...
Published: 8/4/2022
|
Inventor(s):
Jan Frederik Stevens
,
Paul Blakemore
,
Ines Paraiso
,
Luce Mattio
Keywords(s):
Chemical Synthesis
,
medicinal
,
Metabolic syndrome
,
Obesity
,
pharmaceuticals
,
Type 2 Diabetes
Category(s):
Therapeutics
Morpholino Oligomers to Prevent and Treat Coronavirus Infection
This technology licensing opportunity relates to antisense agents for treating or preventing a SARS-CoV-2 infection. The antisense agents are peptide-conjugated morpholino oligomers targeting pre-mRNA of a host (human) gene that encodes a protease. Some antisense agents included within the scope of this technology include agents previously shown to...
Published: 5/26/2021
|
Inventor(s):
Hong Moulton
,
David Stein
,
Eva Bottcher-Friebershauser
Keywords(s):
Category(s):
Therapeutics
Antisense Agents for Treating SARS-CoV-2 Infection
Background In December 2019, cases of an acute respiratory disease were reported from Wuhan, the capital of Hubei province in China. The number of infections increased rapidly and spread to other areas of China and on January 13th, 2020, the first case was reported outside of China. The causative agent was identified as a novel coronavirus (CoV)...
Published: 7/31/2023
|
Inventor(s):
David Stein
,
Hong Moulton
,
Kyle Rosenke
,
Heinrich Feldmann
Keywords(s):
antisense
,
coronavirus
,
covid-19
,
Drug
,
SARS-CoV-2
,
Therapeutic
Category(s):
Therapeutics
New Drugs for Treatment of Type 1 Diabetes
Background Type 1 diabetes (T1D) is a life-threatening autoimmune disease that usually appears in childhood without warning. Current treatment options involve the administration of various insulin analogs and auxiliary therapies. The global market for T1D treatment is over $25 billion and growing. T1D is caused by the immune-mediated destruction...
Published: 6/10/2024
|
Inventor(s):
Siva Kolluri
,
Nancy Kerkvliet
,
Jit Chakravarty
,
Sebastian Bernales
Keywords(s):
Diabetes
,
pharmaceuticals
,
Therapeutic
,
Type 1 Diabetes
Category(s):
Therapeutics
Substituted Phenols and Benzenes for Pharmaceuticals, Agrochemicals and Synthetic Materials
Technology Description This technology licensing opportunity is for novel phenol and benzene compounds with any number of substituents and complete positional selectivity. Synthesis of the compounds is achieved by a new synthetic method. The method provides a one-step conversion of readily available starting materials to give phenols with complete...
Published: 5/23/2023
|
Inventor(s):
Chris Beaudry
,
Xiaojie Zhang
Keywords(s):
agrochemical
,
benzenes
,
chemistry
,
medicinal
,
organic
,
pharmaceuticals
,
phenols
,
polymer
,
substituted
,
synthesis
Category(s):
Agricultural
,
Chemical
,
Therapeutics
Treatment for Hypertension
Technology Description This technology opportunity provides antisense oligomer compounds and methods for the treatment of hypertension that overcome the various limitations and drawbacks associated with the use of substrate inhibitors. The compounds accumulate in the kidney, which allows for efficient dosing, and can be developed for transdermal, subcutaneous,...
Published: 1/16/2023
|
Inventor(s):
Patrick Iversen
,
Andrew Annalora
Keywords(s):
Hypertension
,
pharmaceuticals
,
Transplantation
Category(s):
Therapeutics
Synthetic Cephalotaxine Synthesis and New Anti-Cancer Compounds
Technology Description Oregon State University is seeking a licensee for an improved method to synthesize chemotherapeutic Homoharringtonine (HHT) that overcomes the need to use plant derived cephalotaxine. The synthetic method provides a high yield of chemically synthesized cephalotaxine as an HHT precursor and also enables the synthesis of novel...
Published: 1/13/2023
|
Inventor(s):
Chris Beaudry
,
Xuan Ju
Keywords(s):
Category(s):
Biological Materials
,
Chemical
,
Therapeutics
1
2
3
Home
|
Search
|
RSS
|
Subscribe
© 2024. All Rights Reserved. Powered by
Inteum